Bristol-Myers Squibb

BMY

Market cap $92.8B

Overview Fund Activity

45.60 USD

-0.55

1.19%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

45.61

+0.01

0.02%

1 day

-1.19%

5 days

-3.84%

1 month

-5.37%

3 months

-2.65%

6 months

-23.87%

Year to date

-19.7%

1 year

-8.32%

5 years

-23.06%

10 years

-29.13%

About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Employees: 34,100

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.05% more ownership

Funds ownership: 78.31% [Q1] → 80.36% (+2.05%) [Q2]

8% less funds holding

Funds holding: 2,444 [Q1] → 2,249 (-195) [Q2]

12% less call options, than puts

Call options by funds: $1.12B | Put options by funds: $1.26B

21% less repeat investments, than reductions

Existing positions increased: 805 | Existing positions reduced: 1,014

22% less capital invested

Capital invested by funds: $97.1B [Q1] → $75.7B (-$21.4B) [Q2]

50% less first-time investments, than exits

New positions opened: 150 | Existing positions closed: 302

54% less funds holding in top 10

Funds holding in top 10: 35 [Q1] → 16 (-19) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$34

25% downside

Avg. target

$41

11% downside

High target

$47

3% upside

2 analyst ratings

0 positive

0%

1 neutral

50%

1 negative

50%

Citigroup Andrew Baum	$47	Neutral Maintained	1 Aug 2025
Morgan Stanley Terence Flynn	$34	Underweight Maintained	10 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 39 articles about BMY published over the past 30 days

Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends

The Dividend Harvesting Portfolio reached all-time highs, up 34.27% on invested capital and producing $2,573.68 in forward annualized dividend income. Recent additions include NNN REIT, Bristol Myers, and Starwood Property Trust, all positioned to benefit from upcoming Fed rate cuts. Diversification remains key, with a balanced mix of equities, REITs, ETFs, CEFs, and BDCs driving robust income growth and risk mitigation.

Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends

J&J's experimental psoriasis drug shows promise against Bristol's treatment

Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.

J&J's experimental psoriasis drug shows promise against Bristol's treatment

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

Bristol Myers Squibb Announces Dividend

Bristol Myers to sell 60% stake in China joint venture

U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.

Bristol Myers to sell 60% stake in China joint venture

10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy

Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as undervalued winners and recommended as buys for income-focused investors.

10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy

These stock-market experts don't love AI. Here's what they do recommend.

I'll bet you think that investment newsletters' most-recommended stock is Nvidia Corp., the AI-chip-producing giant whose stock has gained more than 30,000% over the past decade.

These stock-market experts don't love AI. Here's what they do recommend.

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum.

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

24/7 Wall Street

5 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

Dividend stocks are a favorite among investors for good reason. They provide a steady stream of passive income and offer a promising avenue for total return.

5 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.

Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500

Zacks Investment Research

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

See News Rankings

Charts implemented using Lightweight Charts™